Antiretroviral Therapy
Active Resources: 60
Antiretroviral Guidelines
-
7/20/2018
-
10/27/2017
-
8/6/2015 (reviewed: 10/19/2017)
-
3/3/2015 (reviewed: 4/27/2017)
Charts, Tables & Posters
-
6/20/2018
-
7/1/2016
-
9/4/2015
-
7/1/2015
-
2/23/2015
-
1/28/2015
-
12/22/2014
Webinar Recordings
-
3/21/2018
-
1/12/2017
-
12/2/2016
-
6/8/2016
-
10/26/2015
-
7/1/2015
-
2/19/2015
Pocket Guides
-
3/12/2018
-
4/1/2015
-
2/1/2014
Clinical Reference Tools
-
2/1/2018
-
5/3/2017 (reviewed: 5/3/2017)
-
4/28/2017
Slide Sets
-
1/9/2018
-
9/26/2017
-
4/28/2017
-
12/15/2015
-
6/11/2015
-
5/19/2015
-
5/19/2015
-
12/22/2014 (reviewed: 7/17/2015)
-
1/15/2014
Online Training
-
10/20/2017
-
8/23/2017
-
9/15/2016
Curricula
-
9/15/2017
Fact Sheets
-
7/27/2017
-
2/1/2007
Online and Self-Paced Learning
-
12/7/2016
-
10/26/2016
-
10/12/2016
Toolkits
-
5/17/2016
-
7/31/2014 (reviewed: 2/12/2018)
Image Library
-
4/6/2016
Primary Care Guidelines
-
11/9/2015
-
10/29/2014
-
11/13/2013
Coinfection Guidelines (Hep, TB, STIs)
-
6/5/2015
-
3/27/2014 (reviewed: 10/31/2016)
Articles & Bibliographies
-
3/24/2015
-
4/21/2014
-
4/21/2014
-
2/14/2014
Reports
-
2/6/2015
Prevention & Testing Guidelines (PEP, PrEP, PWP)
-
12/11/2014
-
5/14/2014
Videos
-
7/17/2014
Patient Information
-
7/7/2014
-
9/29/2013 (reviewed: 2/24/2017)
Archive Resources: 30
Clinical Reference Tools
-
9/10/2015
Manuals
-
4/30/2014
Videos
-
9/2/2013
-
12/21/2012
Pocket Guides
-
7/1/2013
-
4/1/2013
-
1/1/2008
Charts, Tables & Posters
-
6/1/2013 (reviewed: 1/11/2017)
-
1/1/2013
-
7/1/2011
-
4/1/2008
Webinar Recordings
-
3/19/2013
Curricula
-
11/1/2012
-
9/1/2009
Slide Sets
-
7/1/2012
-
7/8/2011
-
7/1/2007
-
8/15/2006
-
8/1/2006
-
6/1/2006
-
3/1/2006
-
1/1/2006
-
1/1/2006
Fact Sheets
Antiretroviral Guidelines
-
3/5/2012
Reports
-
8/31/2011
Self-Study Materials
-
1/1/2010
Primary Care Guidelines
-
1/1/2008
Patient Information
-
1/1/2005
Articles: 20
-
U=U in PARTNER2 Study of MSM
PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).
PARTNER1 evaluated HIV...
-
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with...
-
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects
On May 18, 2018, the U.S. Food and Drug Administration and the World Health Organization announced that cases of neural tube defects have been reported in babies of women with HIV who were on treatment with dolutegravir at the time of conception and during early pregnancy. The...
-
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing...
-
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...
-
Bictegravir Approved for Initial ART, in Combination with TAF/FTC
Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen for patients who are already on a suppressive ART regimen and who have no history of...
-
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission
In September 2017, the U.S. Centers for Disease Control and Prevention (CDC) officially recognized that suppressing HIV through antiretroviral therapy (ART) prevents sexual transmission of HIV. In a "Dear Colleague" letter, CDC officials said, "people who take ART daily as prescribed and...
-
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...
-
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-...
-
Bictegravir in Initial Therapy
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
CROI 2017: Failure of Dolutegravir Monotherapy
Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...
-
HIV Meds Update - RAPID: Immediate ART Initiation
This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who...
-
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052
The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples...
-
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
Switching from TDF/FTC to TAF/FTC
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
-
Tissue Levels of TAF: Too Low for PrEP?
A pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue and in anogenital fluid samples after administration of oral tenofovir...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...
-
Cobicistat and Stribild Use in Patients with Renal Insufficiency
Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat in patients with mild-to-moderate renal...
| Day | Title |
|---|---|
|
9/28 |
|
|
10/2 |
The Facts
Event type: Conferences & Events
|
|
10/10 |
|
|
10/15 |
|
|
11/8 |
|
|
11/15 |
National Rural Health Day
Event type: Awareness Days
|
|
11/30 |
|
|
12/1 |
World AIDS Day
Event type: Awareness Days
|
|
12/3 |
|
|
12/9 |
|
|
2/7 |
National Black HIV/AIDS Awareness Day
Event type: Awareness Days
|
|
4/11 |
ACTHIV Conference 2019
Event type: Conferences & Events
|
| Day | Title |
|---|---|
|
9/13 |
|
|
5/10 |
|
|
3/4 |
CROI 2018: Boston
Event type: Conferences & Events
|
|
1/18 |